TY - JOUR AU - Brian C. Betts, AU - Joseph Pidala, AU - Jongphil Kim, AU - Asmita Mishra, AU - Taiga Nishihori, AU - Lia Perez, AU - Jose Leonel Ochoa-Bayona, AU - Farhad Khimani, AU - Kelly Walton, AU - Ryan Bookout, AU - Michael Nieder, AU - Divis K. Khaira, AU - Marco Davila, AU - Melissa Alsina, AU - Teresa Field, AU - Ernesto Ayala, AU - Frederick L. Locke, AU - Marcie Riches, AU - Mohamed Kharfan-Dabaja, AU - Hugo Fernandez, AU - Claudio Anasetti, PY - 2017/04/30 Y2 - 2024/03/29 TI - IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation JF - Haematologica JA - haematol VL - 102 IS - 5 SE - Articles DO - 10.3324/haematol.2016.153072 UR - https://haematologica.org/article/view/8075 SP - 948-957 AB - Graft-versus-host disease (GvHD) remains a major cause of transplant-related mortality. Interleukin-2 (IL-2) plus sirolimus (SIR) synergistically reduces acute GvHD in rodents and promotes regulatory T cells. This phase II trial tested the hypothesis that IL-2 would facilitate STAT5 phosphorylation in donor T cells, expand regulatory T cells, and ameliorate GvHD. Between 16th April 2014 and 19th December 2015, 20 patients received IL-2 (200,000 IU/m2 thrice weekly, days 0 to +90) with SIR (5–14 ng/mL) and tacrolimus (TAC) (3–7 ng/mL) after HLA-matched related or unrelated allogeneic hematopoietic cell transplantation (HCT). The study was designed to capture an increase in regulatory T cells from 16.0% to more than 23.2% at day +30. IL-2/SIR/TAC significantly increased regulatory T cells at day +30 compared to our published data with SIR/TAC (23.8% vs. 16.0%, P=0.0016; 0.052 k/uL vs. 0.037 k/uL, P=0.0163), achieving the primary study end point. However, adding IL-2 to SIR/TAC led to a fall in regulatory T cells by day +90 and did not reduce acute or chronic GvHD. Patients who discontinued IL-2 before day +100 showed a suggested trend toward less grade II-IV acute GvHD (16.7% vs. 50%, P=0.1475). We surmise that the reported accumulation of IL-2 receptors in circulation over time may neutralize IL-2, lead to progressive loss of regulatory T cells, and offset its clinical efficacy. The amount of phospho-STAT3+ CD4+ T cells correlated with donor T-cell activation and acute GvHD incidence despite early T-cell STAT5 phosphorylation by IL-2. Optimizing IL-2 dosing and overcoming cytokine sequestration by soluble IL-2 receptor may sustain lasting regulatory T cells after transplantation. However, an approach to target STAT3 is needed to enhance GvHD prevention. (clinicaltrials.gov identifier: 01927120). ER -